Obesity and Dyslipidemia

被引:30
作者
Franssen, Remco [1 ]
Monajemi, Houshang [1 ]
Stroes, Erik S. G. [1 ]
Kastelein, John J. P. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1016/j.ecl.2008.06.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The alarming and still increasing prevalence of obesity and associated cardiovascular risk raises much concern. The increase in cardiovascular risk depends to a significant extent on the changes in lipid profiles as observed in obesity These changes are decreased high-density lipoprotein cholesterol and increased triglyceride levels. Much effort has already been expended into the elucidation of the mechanisms behind these obesity-associated lipid changes. Insulin resistance certainly plays a central role and, in addition, both hormonal and neurologic pathways have recently been found to play an important role. This article focuses on the mechanisms involved in the development of the proatherogenic lipid changes associated with obesity.
引用
收藏
页码:623 / +
页数:12
相关论文
共 59 条
[1]  
Abdel-Maksoud Madiha F, 2002, Semin Vasc Med, V2, P325, DOI 10.1055/s-2002-35403
[2]   Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease [J].
Abrams, GA ;
Kunde, SS ;
Lazenby, AJ ;
Clements, RH .
HEPATOLOGY, 2004, 40 (02) :475-483
[3]   Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia [J].
Adiels, M ;
Borén, J ;
Caslake, MJ ;
Stewart, P ;
Soro, A ;
Westerbacka, J ;
Wennberg, B ;
Olofsson, SO ;
Packard, C ;
Taskinen, MR .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (08) :1697-1703
[4]   Adipose tissue as an endocrine organ [J].
Ahima, Rexford S. .
OBESITY, 2006, 14 :242-249
[5]   Leptin regulation of neuroendocrine systems [J].
Ahima, RS ;
Saper, CB ;
Flier, JS ;
Elmquist, JK .
FRONTIERS IN NEUROENDOCRINOLOGY, 2000, 21 (03) :263-307
[6]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[7]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[8]  
2-S
[9]   Treatment of nonalcoholic fatty liver: Present and emerging therapies [J].
Angulo, P ;
Lindor, KD .
SEMINARS IN LIVER DISEASE, 2001, 21 (01) :81-88
[10]   High-density lipoprotein function - Recent advances [J].
Ansell, BJ ;
Watson, KE ;
Fogelman, AM ;
Navab, M ;
Fonarow, GC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (10) :1792-1798